Foster Group Inc. Purchases 1,519 Shares of Johnson & Johnson $JNJ

Key Points

• Foster Group Inc. increased its stake in Johnson & Johnson by 34.4% during Q2, now owning 5,935 shares valued at $907,000.
• Several institutional investors boosted their investments in Johnson & Johnson, with a total of 69.55% of the company's stock owned by institutional shareholders.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, translating to a 3.0% yield for investors.

Foster Group Inc. grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 34.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,935 shares of the company's stock after acquiring an additional 1,519 shares during the quarter. Foster Group Inc.'s holdings in Johnson & Johnson were worth $907,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $49,000. Finally, Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $50,000. Institutional investors own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. Citigroup boosted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. Bank of America boosted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. The Goldman Sachs Group boosted their price objective on Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a report on Friday. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Tuesday, September 16th. Finally, Guggenheim restated a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $178.80.

Johnson & Johnson Trading Down 1.1%

JNJ opened at $174.22 on Tuesday. The firm has a market cap of $419.58 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 2.24 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The stock has a fifty day moving average price of $173.14 and a 200-day moving average price of $161.69.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.